GEMAYEL GEORGES 4

What Happened Georges Gemayel, a director of Supernus Pharmaceuticals (SUPN), was granted two restricted stock unit (RSU) awards on February 18, 2026 totaling 7,966 RSUs (2,989 RSUs + 4,977 RSUs). Each RSU was granted at $0.00 (award/derivative), meaning no cash purchase occurred; the RSUs represent the right to receive one share of Supernus common stock upon vesting on February 18, 2027.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 20, 2026 (appears timely).
• Awards: 2,989 RSUs and 4,977 RSUs, total 7,966 RSUs; per filing price = $0.00 (code A — award/grant).
• Settlement/vesting: Footnote F1/F2 — each RSU equals one share and will be settled in common stock upon vesting on February 18, 2027.
• Footnote F3 notes options vest on February 18, 2027, though no option exercises were reported in this filing.
• Shares owned after the transaction: not specified in the provided filing details.

Context RSU grants are common compensation for directors and do not represent an immediate cash investment or sale; they convert to shares only if/when they vest. Such awards are routine and meant for long-term alignment with shareholders; they should be interpreted as compensation rather than a direct bullish purchase signal.